Published in:
25-08-2022 | Crohn's Disease | Original Article
The Prevalence of Concomitant Skip Small Bowel Lesions in Crohn’s Disease and Their Effects on Reoperation in Patients Undergoing Ileocolic Resection
Authors:
Wenwei Qian, Lei Gao, Liangyu Huang, Zhen Guo, Lei Cao, Jianfeng Gong, Yi Li, Weiming Zhu
Published in:
Journal of Gastrointestinal Surgery
|
Issue 11/2022
Login to get access
Abstract
Aims
Concomitant lesions in the small intestine are common in Crohn’s disease (CD). This study aimed to detect the incidence of small bowel (SB) lesions in patients undergoing surgical resection for symptomatic ileocolic disease and whether concomitant SB lesions are associated with reoperation due to recurrent CD.
Methods
In this observational, historical cohort study, consecutive patients with CD undergoing primary ileocolic resection (ICR) from 2007 to 2019 were included. Clinical variables and intraoperative findings were extracted from a prospectively maintained database and analyzed by Cox proportional hazards regression models for identifying risk factors of reoperation.
Results
Of the 404 patients included, there were 202 (50%) patients having concomitant SB lesions, and 108 of them underwent concurrent surgical intervention for SB lesions whereas 94 did not. The presence of concomitant SB lesions was a risk factor for reoperation (p = 0.041). Subgroup analysis indicated that patients with concomitant uncomplicated SB lesions left in situ had a comparable rate of reoperation (p = 0.605) whereas patients having concomitant complicated SB lesions undergoing simultaneous surgical intervention showed a higher reoperation rate (P = 0.006) when compared with those without concomitant SB lesions. Interestingly, the adverse effects of concomitant SB lesions can be reversed in the setting of postoperative anti-TNF agents [HR 0.2; 95% CI (0.04–0.9); P=0.040].
Conclusions
Concomitant SB lesion(s), especially those complicated lesions, could be a risk factor for postoperative surgical recurrence in patients undergoing ICR. Active postoperative management strategies such as anti-TNF agents should be provided for these patients.